Loading clinical trials...
Loading clinical trials...
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of FD-001 in Patients with Relapsed or Refractory Hematological Malignancies.
Conditions
Interventions
FD-001
Locations
1
China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Start Date
March 11, 2024
Primary Completion Date
January 24, 2026
Completion Date
March 1, 2026
Last Updated
December 17, 2024
NCT06859424
NCT06994676
NCT05442515
NCT07450872
NCT06158828
NCT03050268
Lead Sponsor
Chengdu FenDi Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions